Wealth Watch Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Wealth Watch Advisors’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-13	Closed	-$299	–	691
2025 Q4	$299	Hold	13	–	–	﹤0.01%	908
2025 Q3	$391	Buy	+13	New	+$390	﹤0.01%	869

Other funds holding RARE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Wealth Watch Advisors's RARE Position: Q1 2026 in Review

Wealth Watch Advisors sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2026, closing a stake of 13 shares — an estimated $299 sold.

Wealth Watch Advisors first reported a position in RARE in Q3 2025 and held it in 2 quarters. The position peaked at $391 in Q3 2025. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

Wealth Watch Advisors reported no remaining Ultragenyx Pharmaceutical position as of Q1 2026 after selling out during the quarter.
Wealth Watch Advisors sold 13 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $299.
Wealth Watch Advisors first reported a position in Ultragenyx Pharmaceutical in Q3 2025 and held it in 2 quarters.
Wealth Watch Advisors's Ultragenyx Pharmaceutical position peaked at $391 in Q3 2025.
295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Wealth Watch Advisors's 13F filing for Q1 2026, filed 15 May 2026.